1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. (1st January 2018)
- Record Type:
- Journal Article
- Title:
- 1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. (1st January 2018)
- Main Title:
- 1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders
- Authors:
- Benek, Ondrej
Hroch, Lukas
Aitken, Laura
Gunn-Moore, Frank
Vinklarova, Lucie
Kuca, Kamil
Perez, Daniel I.
Perez, Concepcion
Martinez, Ana
Fisar, Zdenek
Musilek, Kamil - Abstract:
- Abstract: Several neurodegenerative disorders including Alzheimer's disease (AD) have been connected with deregulation of casein kinase 1 (CK1) activity. Inhibition of CK1 therefore presents a potential therapeutic strategy against such pathologies. Recently, novel class of CK1-specific inhibitors with N -(benzo[ d ]thiazol-2-yl)-2-phenylacetamide structural scaffold has been discovered. 1-(benzo[ d ]thiazol-2-yl)-3-phenylureas, on the other hand, are known inhibitors amyloid-beta binding alcohol dehydrogenase (ABAD), an enzyme also involved in pathophysiology of AD. Based on their tight structural similarity, we decided to evaluate series of previously published benzothiazolylphenylureas, originally designed as ABAD inhibitors, for their inhibitory activity towards CK1. Several compounds were found to be submicromolar CK1 inhibitors. Moreover, two compounds were found to inhibit both, ABAD and CK1. Such dual-activity could be of advantage for AD treatment, as it would simultaneously target two distinct pathological processes involved in disease's progression. Based on PAMPA testing both compounds were suggested to permeate the blood-brain barrier, which makes them, together with their unique dual activity, interesting lead compounds for further development. Graphical Abstract:
- Is Part Of:
- Journal of enzyme inhibition and medicinal chemistry. Volume 33:Number 1(2018)
- Journal:
- Journal of enzyme inhibition and medicinal chemistry
- Issue:
- Volume 33:Number 1(2018)
- Issue Display:
- Volume 33, Issue 1 (2018)
- Year:
- 2018
- Volume:
- 33
- Issue:
- 1
- Issue Sort Value:
- 2018-0033-0001-0000
- Page Start:
- 665
- Page End:
- 670
- Publication Date:
- 2018-01-01
- Subjects:
- Alzheimer's disease -- amyloid-beta binding alcohol dehydrogenase (ABAD) -- benzothiazole -- casein kinase 1 (CK1) -- neurodegeneration
Enzyme inhibitors -- Periodicals
Enzyme Inhibitors -- periodicals
Biochemistry -- periodicals
572.7 - Journal URLs:
- http://informahealthcare.com/loi/enz ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/14756366.2018.1445736 ↗
- Languages:
- English
- ISSNs:
- 1475-6366
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4979.465000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11947.xml